Castle Hook Partners LP Takes $38.06 Million Position in NewAmsterdam Pharma Company N.V. $NAMS

Castle Hook Partners LP purchased a new stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the fourth quarter, Holdings Channel.com reports. The firm purchased 1,085,008 shares of the company’s stock, valued at approximately $38,062,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Artia Global Partners LP increased its holdings in shares of NewAmsterdam Pharma by 158.6% in the 4th quarter. Artia Global Partners LP now owns 503,936 shares of the company’s stock valued at $17,678,000 after acquiring an additional 309,098 shares during the period. Guggenheim Capital LLC purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $224,000. Logos Global Management LP acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth $15,786,000. ADAR1 Capital Management LLC boosted its position in shares of NewAmsterdam Pharma by 3.7% in the 4th quarter. ADAR1 Capital Management LLC now owns 118,623 shares of the company’s stock worth $4,161,000 after purchasing an additional 4,264 shares in the last quarter. Finally, Jain Global LLC acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth $1,669,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $869,158.57. The trade was a 72.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $30.15 on Thursday. The business has a fifty day moving average price of $33.26 and a 200-day moving average price of $33.42. NewAmsterdam Pharma Company N.V. has a 1-year low of $17.63 and a 1-year high of $42.21. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of -16.84 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The firm had revenue of $3.04 million for the quarter. On average, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on NAMS. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Needham & Company LLC raised their price objective on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $48.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.